Core Viewpoint - Company will showcase its pipeline asset CS2015 at the 2025 ACAAI annual scientific meeting, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulatory factors that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website [1]
基石药业-B(02616)：ACAAI 2025 | CS2015(OX40L/TSLP双特异性抗体)首次亮相国际学术舞台